The present invention provides compounds of formula (I), formula (II) or formula (III), wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

##STR00001##

A metal substrate being coated on at least a portion thereof with a liquid coating composition comprising a powder component dispersed in a liquid carrier, wherein the average particle size of the powder dispersed in the liquid carrier is less than 15 microns (m); wherein the powder component comprises a thermoset resin; wherein the thermoset resin comprises an acid functional polyester material; and wherein the coating composition is substantially free of bisphenol A (BPA), bisphenol F (BPF), bisphenol A diglycidyl ether (BADGE) and bisphenol F diglycidyl ether (BFDGE).

A metal substrate being coated on at least a portion thereof with a liquid coating composition comprising a powder component dispersed in a liquid carrier, wherein the average particle size of the powder dispersed in the liquid carrier is less than 15 microns (m); wherein the powder component comprises a thermoset resin; wherein the thermoset resin comprises an acid functional polyester material; and wherein the coating composition is substantially free of bisphenol A (BPA), bisphenol F (BPF), bisphenol A diglycidyl ether (BADGE) and bisphenol F diglycidyl ether (BFDGE).

A powder coating composition comprising: a) a thermoset resin comprising an acid functional polyester material, b) a thermoplastic resin and c) a crosslinker material, wherein the coating composition is substantially free of bisphenol A (BPA), bisphenol F (BPF), bisphenol A diglycidylether (BADGE) and bisphenol F diglycidyl ether (BFDGE).

A powder coating composition comprising: a) a thermoset resin comprising an acid functional polyester material, b) a thermoplastic resin and c) a crosslinker material, wherein the coating composition is substantially free of bisphenol A (BPA), bisphenol F (BPF), bisphenol A diglycidylether (BADGE) and bisphenol F diglycidyl ether (BFDGE).

Compounds and methods for inhibiting cofilin activity or reducing total cofilin, improving motor deficits, attenuating LPS-induced microglial activation and inflammation, reducing microglial migration and proliferation, reducing TNF-, reducing NF-B, and improving motor deficits in a subject are described.

Compounds and methods for inhibiting cofilin activity or reducing total cofilin, improving motor deficits, attenuating LPS-induced microglial activation and inflammation, reducing microglial migration and proliferation, reducing TNF-, reducing NF-B, and improving motor deficits in a subject are described.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described.